The Sonablate is a state-of-the art, non-invasive medical device that destroys tissue in the prostate using focused ultrasound.
The Sonablate was approved by the FDA in October 2015 and was the first HIFU device to receive regulatory authorization from the FDA for ablation of prostate tissue.
This state-of-the-art technology consists of a console where the physician plans, monitors and adjusts HIFU treatment, a transrectal probe and a chiller, which is a safety device that keeps the rectum cool during treatment.
Sonablate was the first device to receive regulatory authorization from the FDA for the ablation of prostate tissue with HIFU.
How Sonablate treats the prostate
The Sonablate device has highly sophisticated software that enables treating physicians to obtain images of the prostate. The images are used to map out and target exactly where HIFU should be delivered.
Once a physician has targeted all the areas to be treated, he then delivers the HIFU energy, while continually monitoring how the tissue reacts; making adjustments as needed, for safe, effective delivery of HIFU energy.
Why Choose Sonablate HIFU?
HIFU is a noninvasive, outpatient treatment option that allows men to return to their normal lifestyle immediately, preserving patient quality of life.
The Sonablate is the most sophisticated HIFU technology available for prostate tissue ablation. The Sonablate incorporates customized treatment and safety technologies in an effort to strike a balance that has previously been difficult to achieve in prostate cancer treatment—increasing disease control capabilities, while decreasing quality-of-life side effects.